FDA-2024-0061
This application view consolidates identifiers, linked product and market authorization context, dossier structure, sequence history, and active authority obligations in one place. Regulatory teams use it to understand readiness and risk before publishing new sequences or responding to open questions. Cross-links to labeling and variations maintain lifecycle traceability for post-approval changes. Inspection readiness risk is calculated from overdue commitments, failed sequences, and unresolved high-risk correspondence for immediate action.
Application ID
APP-061
Application Number
FDA-2024-0061
Procedure Type
NDA
Status
Active
Linked Product
Market Authorization
United States · FDA
Dossier Structure View
| Dossier | Format | Version | Modules | Module Breakdown | Status |
|---|---|---|---|---|---|
| DOS-061 | NeeS | 5.4.2 | 5 | M1 (11), M2 (9), M3 (7), M4 (5), M5 (12) | Pending |
Sequence Timeline
Open Questions and Commitments
| Question | Due Date | Risk | Status |
|---|---|---|---|
| Request for post-marketing commitment progress update | 2025-03-20 | medium | Overdue |
| Request for updated SmPC section 4.1 | 2025-02-15 | low | Draft |
| Request for benefit-risk assessment addendum | 2025-02-27 | medium | Draft |
| Information request: manufacturing process change justification | 2024-12-03 | high | Open |
| Commitment | Due Date | Priority | Status |
|---|---|---|---|
| Implement Risk Minimisation Measures (RMM) per REMS requirements | 2025-03-15 | high | In Progress |
Linked Labeling and Variations
| Labeling Artifact | Type | Version | Status |
|---|---|---|---|
| LBL-181 | IFU | 14.6 | Active |
| Variation | Type | Status | Submitted |
|---|---|---|---|
| FDA-2024-0061-V061 | Major | Approved | 2022-12-11 |
| FDA-2024-0061-V161 | Type IB | Pending | 2023-06-10 |
| FDA-2024-0061-V261 | Minor | Active | 2022-09-12 |
| FDA-2024-0061-V361 | Major | Failed | pending |
| FDA-2024-0061-V461 | Type IA | Active | 2024-02-09 |
Inspection Readiness Risk Panel
Risk Score: 1 · Overdue commitments: 0, failed/blocked sequences: 0, high-risk questions: 1.
Recommended next step: resolve outstanding questions and commitments before next publishing cycle to reduce inspection exposure.